专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08263557B2 Method and mixture for in vivo photochemical cross-linking of collagen 有权
标题翻译：胶原蛋白体内光化学交联的方法和混合物
公开(公告)号：US08263557B2
公开(公告)日：2012-09-11
申请号：US12227079
申请日：2007-07-27
申请人： Susanna Gräfe , Wolfgang Neuberger , Danilo Castro
发明人： Susanna Gräfe , Wolfgang Neuberger , Danilo Castro
IPC分类号： A61K38/17 , C07D487/22 , A61N5/06
CPC分类号： A61K31/33 , A61K9/0019 , A61K9/127 , A61K47/24
摘要： A method and a composition for photochemical cross linking of collagen by photoactive agent in-vivo are presented. The method includes a non-toxic photoactive formulation of the composition with collagen, which is administered to treatment area locally; followed by irradiation with suitable wavelength. In one of the embodiment liposomal formulated mTHPC is added to the collagen and is irradiated with a 652 nm laser, resulting in producing efficient collagen scaffolds with strengthen and stabilized microstructure, thus improving the physiochemical properties of the collagen scaffold. It improves the thermostability, mechanical property and swelling ratio of newly formed scaffold. Photochemical cross-linked collagens shows antimicrobial effect, when irradiated with suitable wavelength it disinfects the treatment site and curbs microbial growth.
摘要翻译：提出了通过光活性剂在体内对胶原蛋白的光化学交联的方法和组合物。该方法包括具有胶原蛋白的组合物的无毒光活性制剂，其局部施用于治疗区域; 然后用合适的波长照射。在其中一个实施方案中，将脂质体配制的mTHPC加入到胶原中并用652nm激光照射，从而产生具有强化和稳定的微结构的有效的胶原支架，从而改善胶原支架的物理化学性质。提高新型脚手架的热稳定性，机械性能和溶胀比。光化学交联胶原显示抗菌效果，当用合适的波长照射时，其消毒处理部位并抑制微生物生长。

2. 发明申请

US20090171262A1 Method and Mixture for In Vivo Photochemical Cross-Linking of Collagen 有权
标题翻译：胶原蛋白体内光化学交联的方法和混合物
公开(公告)号：US20090171262A1
公开(公告)日：2009-07-02
申请号：US12227079
申请日：2007-07-27
申请人： Susanna Gräfe , Wolfgang Neuberger , Danilo Castro
发明人： Susanna Gräfe , Wolfgang Neuberger , Danilo Castro
IPC分类号： A61N5/06 , A61K38/16
CPC分类号： A61K31/33 , A61K9/0019 , A61K9/127 , A61K47/24
摘要： A method and a composition for photochemical cross linking of collagen by photoactive agent in-vivo are presented. The method includes a non-toxic photoactive formulation of the composition with collagen, which is administered to treatment area locally; followed by irradiation with suitable wavelength. In one of the embodiment liposomal formulated mTHPC is added to the collagen and is irradiated with a 652 nm laser, resulting in producing efficient collagen scaffolds with strengthen and stabilized microstructure, thus improving the physiochemical properties of the collagen scaffold. It improves the thermo stability, mechanical property and swelling ratio of newly formed scaffold. Photochemical cross-linked collagens shows antimicrobial effect, when irradiated with suitable wavelength it disinfects the treatment site and curbs microbial growth.
摘要翻译：提出了通过光活性剂在体内对胶原蛋白的光化学交联的方法和组合物。该方法包括具有胶原蛋白的组合物的无毒光活性制剂，其局部施用于治疗区域; 然后用合适的波长照射。在其中一个实施方案中，将脂质体配制的mTHPC加入到胶原中并用652nm激光照射，从而产生具有强化和稳定的微结构的有效的胶原支架，从而改善胶原支架的物理化学性质。提高新成型脚手架的热稳定性，机械性能和溶胀比。光化学交联胶原显示抗菌效果，当用合适的波长照射时，其消毒处理部位并抑制微生物生长。

3. 发明授权

US08986731B2 Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy 有权
标题翻译：用于光动力学治疗的疏水性光敏剂的聚乙二醇化脂质体制剂
公开(公告)号：US08986731B2
公开(公告)日：2015-03-24
申请号：US11349405
申请日：2006-02-07
申请人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Gräfe , Wolfgang Neuberger
发明人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Gräfe , Wolfgang Neuberger
IPC分类号： A61K9/127 , A61K31/407 , A61K31/555 , A61K41/00
CPC分类号： A61K9/1271 , A61K31/407 , A61K31/555 , A61K41/0071
摘要： Pharmaceutical pegylated liposomal formulations for photodynamic therapy are presented. The pegylated liposomal formulation provides therapeutically effective amounts of the photosensitizer for intravenous administration. At least one of the phospholipids in the liposomes has been linked with poly ethylene glycol (PEG) as an integral part of the phospholipids. The formed pegylated liposomes contain the hydrophobic photosensitizer within the lipid bilayer membrane. Pegylation of liposomes carrying the hydrophobic photosensitizer helps to maintain the drug level within the therapeutic window for longer time periods and provides the drug a longer circulating half life in vivo. Further the pegylated formulation of hydrophobic photosensitizers shows improved pharmacokinetics over standard non-liposomal formulations thus enhancing the efficacy of PDT with the pegylated liposomal formulations.
摘要翻译：提出了用于光动力学治疗的药物聚乙二醇化脂质体制剂。聚乙二醇化脂质体制剂提供治疗有效量的用于静脉内施用的光敏剂。脂质体中的至少一种磷脂已经与作为磷脂的组成部分的聚乙二醇（PEG）连接。形成的聚乙二醇化脂质体在脂质双层膜内含有疏水性光敏剂。携带疏水性光敏剂的脂质体的聚乙二醇化有助于在治疗窗口内维持更长时间的药物水平，并使药物在体内延长循环半衰期。此外，疏水性光敏剂的聚乙二醇化制剂显示与标准非脂质体制剂相比改善的药物代谢动力学，从而增强PDT与聚乙二醇化脂质体制剂的功效。

4. 发明申请

US20120101427A1 NOVEL PHOTOSENSITIZER FORMULATIONS FOR ORAL ADMINISTRATION 审中-公开
标题翻译：用于口腔管理的新型光敏剂配方
公开(公告)号：US20120101427A1
公开(公告)日：2012-04-26
申请号：US13266056
申请日：2009-04-28
申请人： Gerard Farmer , Gerhard Wieland , Dietrich Scheglmann , Arno Wiehe , Susanna Gräfe , Nikolay E. Nufantiev , Volker Albrecht , Wolfgang Neuberger
发明人： Gerard Farmer , Gerhard Wieland , Dietrich Scheglmann , Arno Wiehe , Susanna Gräfe , Nikolay E. Nufantiev , Volker Albrecht , Wolfgang Neuberger
IPC分类号： A61M37/00 , A61K31/498 , C07D487/22 , C07D241/46 , A61K9/127 , A61K38/02 , A61K31/7056 , A61K31/706 , A61K31/79 , A61P35/00 , A61P17/00 , A61P9/00 , A61P19/02 , A61P31/04 , A61P33/02 , A61P31/12 , A61P31/00 , A61K31/409 , B82Y5/00
CPC分类号： A61K31/122 , A61K31/40 , A61K31/498 , A61K41/0071
摘要： The present invention provides novel drug formulations for oral administration for diverse medical applications including anticancer, antimetastatic, antibacterial, antifungal, antiprotozoic, antiviral, antiprionic and PDT treatments for diagnostic and therapeutic purposes. In a preferred embodiment the oral drug formulation comprises a photosensitizer and suitable excipients and may be administered in multiple doses over an extended period of time with exposure to activating radiation occurring generally between individual doses or in a light-independent manner. In another preferred embodiment PDT methods for treating hyperplasia and neoplasia, for localizing hyperplasic and neoplasic tissues and pathogen bacteria by fluorescence, for treating infections caused by pathogen bacteria in complex body fluids and for fat reduction, skin disorders and vascular diseases are provided.
摘要翻译：本发明提供用于口服给药以用于各种医学应用的新型药物制剂，包括用于诊断和治疗目的的抗癌，抗转移，抗细菌，抗真菌，抗原生动脉，抗病毒，抗细胞和PDT治疗。在优选的实施方案中，口服药物制剂包含光敏剂和合适的赋形剂，并且可以在延长的时间段内以多个剂量施用，暴露于通常在单独剂量之间或以轻轻独立的方式发生的活化辐射。在另一个优选实施方案中，提供了用于治疗增生和瘤形成的PDT方法，用于通过荧光定位超基质和新生组织和病原体细菌，用于治疗复杂体液中由病原体引起的感染和用于减脂，皮肤病和血管疾病。

5. 发明授权

US08815931B2 Oral formulations for tetrapyrrole derivatives 有权
标题翻译：四吡咯衍生物的口服制剂
公开(公告)号：US08815931B2
公开(公告)日：2014-08-26
申请号：US12768244
申请日：2010-04-27
申请人： Susanna Gräfe , Nikolay Nifantiev , Albrecht Volker , Wolfgang Neuberger , Gerhard Wieland , Dietrich Scheglmann , Alfred Fahr , Arno Wiehe
发明人： Susanna Gräfe , Nikolay Nifantiev , Albrecht Volker , Wolfgang Neuberger , Gerhard Wieland , Dietrich Scheglmann , Alfred Fahr , Arno Wiehe
IPC分类号： A61K31/40 , A61K9/127 , A61K31/498 , A61K9/00 , A61K31/409
CPC分类号： A61K31/409 , A61K9/0065 , A61K9/127 , A61K9/1271 , A61K31/498
摘要： Oral formulations and method of formulating photosensitive agents for oral administration during photodynamic therapy (PDT) and Antimicrobial photodynamic therapy (APDT) treatment are presented. The oral formulated photosensitizers show increased solubility and permeability, thus improving the bioavailability of photosensitizers at the treatment site. An orally administered photosensitizer is suitably formulated for mucosal adhesion and absorption via gastrointestinal mucosal membranes. Oral formulation provided herein use lipids and known proteins as carriers for photosensitizers by oral route. Carriers for encapsulating preselected photosensitizers include conventional liposomes, pegylated liposomes, nanoemulsions, nanocrystrals, nanoparticles, fatty emulsions, lipidic formulations, hydrosols, SMEDDS, Alpha-Feto protein (AFP), and Bovine-Serum-Albumin (BSA), fatty emulsions, hot-melt-extrudates and nanoparticles. The oral formulation, in case of a hydrophobic photosensitizer in the present invention, is stabilized using suitable surfactants/solubilizers thus preventing aggregation of the drug in the stomach and until it is absorbed in the duodenum and the small intestine. Oral formulations can be administered in the form of liquid, capsule, tablet, powder, paste or gel. Formulated drugs can be administered orally as one single dose or in multiple doses before administering PDT. In one embodiment Temoporfin (m-THPC) is used as a photosensitizer in the oral formulations. Temoporfin like many hydrophobic photosensitizers are especially suitable to be administered orally because there is no known enzyme system in the mammalian body which can metabolize Temoporfin or similar photosensitizers. Temoporfin can reach the blood system unchanged and fully active after absorption of the formulation in the gastrointestinal tract.
摘要翻译：提出了在光动力治疗（PDT）和抗微生物光动力疗法（APDT）治疗中配制口服光敏剂的口服制剂和方法。口服配制的光敏剂显示增加的溶解度和渗透性，从而提高光敏剂在治疗部位的生物利用度。口服给药的光敏剂适于配制用于通过胃肠粘膜进行粘膜粘附和吸收。本文提供的口服制剂通过口服途径使用脂质和已知蛋白质作为光敏剂的载体。用于封装预选光敏剂的载体包括常规脂质体，聚乙二醇化脂质体，纳米乳剂，纳米胶体，纳米颗粒，脂肪乳剂，脂质制剂，水溶胶，SMEDDS，α-铁蛋白（AFP）和牛血清白蛋白（BSA），脂肪乳剂，热熔融挤出物和纳米颗粒。在本发明的疏水性光敏剂的情况下，使用合适的表面活性剂/增溶剂稳定口服制剂，从而防止药物在胃中的聚集，直到其被吸收到十二指肠和小肠中。口服制剂可以以液体，胶囊，片剂，粉末，糊剂或凝胶的形式施用。配制药物可以在给予PDT之前以一次剂量或多次剂量口服给药。在一个实施方案中，Temoporfin（m-THPC）用作口服制剂中的光敏剂。类似于许多疏水性光敏剂的Temoporfin特别适合于口服给药，因为哺乳动物体内没有已知的可以代谢Temoporfin或类似光敏剂的酶系统。 Temoporfin可以在胃肠道吸收制剂后达到血液系统不变和充分活性。

6. 发明申请

US20100273803A1 Oral Formulations for Tetrapyrrole Derivatives 有权
标题翻译：四吡咯衍生物的口服制剂
公开(公告)号：US20100273803A1
公开(公告)日：2010-10-28
申请号：US12768244
申请日：2010-04-27
申请人： Susanna Gräfe , Nikolay Nifantiev , Albrecht Volker , Wolfgang Neuberger , Gerhard Wieland , Dietrich Scheglmann , Alfred Fahr , Arno Wiehe
发明人： Susanna Gräfe , Nikolay Nifantiev , Albrecht Volker , Wolfgang Neuberger , Gerhard Wieland , Dietrich Scheglmann , Alfred Fahr , Arno Wiehe
IPC分类号： A61K31/498 , C07D241/46 , A61K31/409 , C07D487/22 , A61P35/00 , A61P31/00 , A61K8/49 , A61Q19/00 , A61Q9/00
CPC分类号： A61K31/409 , A61K9/0065 , A61K9/127 , A61K9/1271 , A61K31/498
摘要： Oral formulations and method of formulating photosensitive agents for oral administration during photodynamic therapy (PDT) and Antimicrobial photodynamic therapy (APDT) treatment are presented. The oral formulated photosensitizers show increased solubility and permeability, thus improving the bioavailability of photosensitizers at the treatment site. An orally administered photosensitizer is suitably formulated for mucosal adhesion and absorption via gastrointestinal mucosal membranes. Oral formulation provided herein use lipids and known proteins as carriers for photosensitizers by oral route. Carriers for encapsulating preselected photosensitizers include conventional liposomes, pegylated liposomes, nanoemulsions, nanocrystrals, nanoparticles, fatty emulsions, lipidic formulations, hydrosols, SMEDDS, Alpha-Feto protein (AFP), and Bovine-Serum-Albumin (BSA), fatty emulsions, hot-melt-extrudates and nanoparticles. The oral formulation, in case of a hydrophobic photosensitizer in the present invention, is stabilized using suitable surfactants/solubilizers thus preventing aggregation of the drug in the stomach and until it is absorbed in the duodenum and the small intestine. Oral formulations can be administered in the form of liquid, capsule, tablet, powder, paste or gel. Formulated drugs can be administered orally as one single dose or in multiple doses before administering PDT. In one embodiment Temoporfin (m-THPC) is used as a photosensitizer in the oral formulations. Temoporfin like many hydrophobic photosensitizers are especially suitable to be administered orally because there is no known enzyme system in the mammalian body which can metabolize Temoporfin or similar photosensitizers. Temoporfin can reach the blood system unchanged and fully active after absorption of the formulation in the gastrointestinal tract.
摘要翻译：提出了在光动力治疗（PDT）和抗微生物光动力疗法（APDT）治疗中配制口服光敏剂的口服制剂和方法。口服配制的光敏剂显示增加的溶解度和渗透性，从而提高光敏剂在治疗部位的生物利用度。口服给药的光敏剂适于配制用于通过胃肠粘膜进行粘膜粘附和吸收。本文提供的口服制剂通过口服途径使用脂质和已知蛋白质作为光敏剂的载体。用于封装预选光敏剂的载体包括常规脂质体，聚乙二醇化脂质体，纳米乳剂，纳米胶体，纳米颗粒，脂肪乳剂，脂质制剂，水溶胶，SMEDDS，α-铁蛋白（AFP）和牛血清白蛋白（BSA），脂肪乳剂，热熔融挤出物和纳米颗粒。在本发明的疏水性光敏剂的情况下，使用合适的表面活性剂/增溶剂稳定口服制剂，从而防止药物在胃中的聚集，直到其被吸收到十二指肠和小肠中。口服制剂可以以液体，胶囊，片剂，粉末，糊剂或凝胶的形式施用。配制药物可以在给予PDT之前以一次剂量或多次剂量口服给药。在一个实施方案中，Temoporfin（m-THPC）用作口服制剂中的光敏剂。类似于许多疏水性光敏剂的Temoporfin特别适合于口服给药，因为哺乳动物体内没有已知的可以代谢Temoporfin或类似光敏剂的酶系统。 Temoporfin可以在胃肠道吸收制剂后达到血液系统不变和充分活性。

7. 发明申请

US20110021973A1 FORMULATIONS FOR COSMETIC AND WOUND CARE TREATMENTS WITH PHOTOSENSITIZERS AS FLUORESCENT MARKERS 审中-公开
标题翻译：使用光敏剂作为荧光标记的化妆和治疗护理品的配方
公开(公告)号：US20110021973A1
公开(公告)日：2011-01-27
申请号：US12896614
申请日：2010-10-01
申请人： Wolfgang Neuberger , Susanna Gräfe , Nikolay E. Nifantiev
发明人： Wolfgang Neuberger , Susanna Gräfe , Nikolay E. Nifantiev
IPC分类号： A61M37/00
CPC分类号： A61L27/50
摘要： Photoactive materials, such as photosensitizers, are used as fluorescent markers for in vivo detection of the distribution of the injected filler material during cosmetic treatments. In one preferred embodiment, liposomal formulated temoporfin is used, as the photoactive component, in very small concentrations along with fillers for cosmetic and wound healing applications. Fillers, which can be used in the invention, include collagen, hyaluronic acids and other synthetic or natural products which are generally used in wound healing, scar reduction and other such medical applications. In a preferred embodiment, the formulated photosensitizer is coupled to the filler so that tracking is possible over longer periods of time A liposomal formulated photosensitizer is injected with the fillers into the treatment area, and is irradiated with laser light shortly after injection. The emitted fluorescence is measured by a special non-invasive device. Thereby it is possible to monitor the injection site and the distribution of the injected solution around the injection site. When irradiated with laser or other light source, the fluorescence of the photosensitizer is detected using a fluorescence detector, which permits tracking the filler at injection site and in the injection volume.
摘要翻译：光敏剂如光敏剂被用作荧光标记物，用于在化妆品处理期间体内检测注入的填充材料的分布。在一个优选的实施方案中，作为光活性成分的脂质体配制的temoporfin以非常小的浓度与用于化妆品和伤口愈合应用的填充剂一起使用。可用于本发明的填充剂包括胶原蛋白，透明质酸和通常用于伤口愈合，瘢痕减少等医学应用中的其它合成或天然产物。在优选的实施方案中，将配制的光敏剂偶联到填料，使得可以在更长时间内进行跟踪。将脂质体配制的光敏剂注射到处理区域中，并在注射后不久用激光照射。发射的荧光通过特殊的非侵入性装置测量。因此，可以监测注射部位和注射部位周围注射溶液的分布情况。当用激光或其他光源照射时，使用荧光检测器检测光敏剂的荧光，其允许在注射部位和注射体积中追踪填料。

8. 发明授权

US07354599B2 Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy 有权
标题翻译：用于光动力疗法的疏水性光敏剂的脂质体制剂
公开(公告)号：US07354599B2
公开(公告)日：2008-04-08
申请号：US11298729
申请日：2005-12-09
申请人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Gräfe , Wolfgang Neuberger
发明人： Volker Albrecht , Alfred Fahr , Dietrich Scheglmann , Susanna Gräfe , Wolfgang Neuberger
IPC分类号： A61K9/127
CPC分类号： A61K41/0071 , A61K9/127
摘要： Pharmaceutical liposomal formulations are described for photodynamic therapy comprising a, hydrophobic porphyrin photosensitizer, a monosaccharide and one or more synthetic phospholipids, which are stable in storage especially through freeze-drying process. The liposomal formulations provide therapeutically effective amounts of the photosensitizer for intravenous administration. In particular derivatives of chlorins and bacteriochlorins, such as temoporfin, are, hydrophobic photosensitizers whose efficacy and safety are enhanced by such liposomal formulations. The formulation can be efficiently freeze-dried preserving the size of the liposomal vehicles, and the content of a therapeutically effective amount of the photosensitizer, due to the selection of phospholipids and monosaccharides. The invention also relates to liposome compositions formed upon reconstitution with an aqueous vehicle. The freeze-dried formulation upon reconstitution with a suitable aqueous vehicle forms liposomes that are useful for intravenous administration.
摘要翻译：描述了用于光动力学治疗的药物脂质体制剂，其包括疏水性卟啉光敏剂，单糖和一种或多种合成磷脂，其特别通过冷冻干燥方法在储存中稳定。脂质体制剂提供治疗有效量的用于静脉内给药的光敏剂。特别是二氢卟酚和细菌二氢卟酚的衍生物，如temoporfin，是通过这种脂质体制剂增强其功效和安全性的疏水性光敏剂。由于磷脂和单糖的选择，制剂可以有效地冷冻干燥，保持脂质体载体的大小和治疗有效量的光敏剂的含量。本发明还涉及在用水性载体重建时形成的脂质体组合物。用合适的水性载体重建后的冷冻干燥制剂形成可用于静脉内给药的脂质体。

9. 发明授权

US08801764B2 Cosmetic laser treatment device and method for localized lipodystrophies and flaccidity 有权
标题翻译：化妆品激光治疗装置及局部脂肪营养不良及易感性的方法
公开(公告)号：US08801764B2
公开(公告)日：2014-08-12
申请号：US11415782
申请日：2006-05-02
申请人： Danilo Castro Suarez , Wolfgang Neuberger
发明人： Danilo Castro Suarez , Wolfgang Neuberger
IPC分类号： A61N5/06 , A61B18/20 , A61B18/24 , A61B18/00 , A61B18/22 , A61B17/00
CPC分类号： A61B18/22 , A61B18/20 , A61B18/24 , A61B2017/00792 , A61B2018/00464 , A61B2018/0047 , A61B2018/00577 , A61B2018/2272
摘要： A method and device for cosmetic surgery, especially fat reduction and collagen reformation, by means of a high power laser operating at about 980 nm is presented. The cosmetic surgery method substantially reduces or removes localized lipodystrophies, and essentially reduces flaccidity by localized laser heating of adipose tissue using an optical fiber inserted into a treatment area. The method and device are particularly well suited for treating Lipodystrophies with flaccidity High power laser energy is applied to “fat” cells to breakdown the cell walls releasing the cell fluid. The laser radiation is applied through an optical fiber which may be held within a catheter-like device having a single lumen. The optical fiber may have a diffuser mounted on the tip to further apply heating to tissues surrounding the whole tip. A saline solution may also be inserted into the treatment site to aid in the heating of the fat cells and their eventual destruction as well as their removal. The pool of cell fluid in the area of treatment is removed by a combination of techniques including allowing the body to remove it by absorption and drainage from the entry sites thus minimizing trauma to the area of treatment and hastening recovery. Additional techniques to remove the cell fluid include direct force application by means of elastic bandages and external suction applied to the entry sites. Quick and lasting cosmetic changes, even in areas having prior untreatable fat tissues, are achieved while minimizing trauma to the treatment areas.
摘要翻译：提出了一种用于整容手术的方法和装置，特别是通过在约980nm下操作的高功率激光来减脂和胶原蛋白重整。整容手术方法基本上减少或去除局部的脂肪营养不良，并且通过使用插入到治疗区域中的光纤对脂肪组织的局部激光加热来基本上减少松弛。该方法和装置特别适合用于治疗具有松弛性的脂肪营养不良。大功率激光能量被施加到“脂肪”细胞上以破坏释放细胞液的细胞壁。激光辐射通过可以保持在具有单个管腔的导管状装置内的光纤施加。光纤可以具有安装在尖端上的扩散器，以进一步对整个尖端周围的组织施加加热。也可以将盐水溶液插入治疗部位，以帮助加热脂肪细胞及其最终的破坏以及其去除。治疗区域中的细胞液池通过技术的组合来去除，包括允许身体通过进入部位的吸收和排出而将其去除，从而最小化对治疗区域和加速恢复的创伤。除去细胞液的附加技术包括通过弹性绷带施加的直接力施加和施加到入口部位的外部吸力。即使在具有先前不可治愈的脂肪组织的区域中也能实现快速和持久的化妆品变化，同时最小化治疗区域的创伤。

10. 发明授权

US08414880B2 PDT treatment method for cellulites and cosmetic use 失效
标题翻译：用于脂肪团和化妆品使用的PDT处理方法
公开(公告)号：US08414880B2
公开(公告)日：2013-04-09
申请号：US12899003
申请日：2010-10-06
申请人： Danilo Castro , Wolfgang Neuberger
发明人： Danilo Castro , Wolfgang Neuberger
IPC分类号： A01N63/00
CPC分类号： A61K31/555 , A61K8/494 , A61K31/409 , A61K2800/81 , A61Q19/06
摘要： Photosensitizer mixtures and method of treating cellulites by light illumination are presented. Photosensitizer is combined with cellular products, e.g. adipose cells, collagen, previously removed by liposuction. Concentrations used depend on treatment area, cellulite stage and whether cellulites are in depressed or elevated skin areas. The cosmetic treatment reduces/removes localized lipodystrophies, flaccidity, cellulite using localized laser, LED, etc emissions. Applied light energy destroys “fat” cells by a combination of chemical reactions primarily, and temperature, wherein cell walls break releasing cell fluid. Transmission devices guide radiation to the treatment site. One or more light sources like laser diodes or LEDs may be coupled into one or more optical fibers to increase the covered area and increase the amount of radiation in that area. Optical fibers can be introduced percutaneously or interstitially. Cell fluid in the treatment area is removed by a combination of techniques.
摘要翻译：提出了光敏剂混合物和通过光照照治疗脂肪团的方法。光敏剂与蜂窝产品结合，例如脂肪细胞，胶原蛋白，预先通过吸脂除去。使用的浓度取决于治疗区域，脂肪团阶段以及是否在脂肪团处于抑郁或升高的皮肤区域。化妆处理减少/消除了使用局部激光，LED等排放的局部脂肪营养不良，松弛，脂肪团。应用光能主要通过化学反应的组合和温度破坏脂肪细胞，其中细胞壁破坏释放细胞液体。传输装置将辐射引导到治疗部位。诸如激光二极管或LED的一个或多个光源可以耦合到一个或多个光纤中，以增加覆盖面积并增加该区域中的辐射量。光纤可经皮或间质引入。通过技术的组合来去除处理区域中的细胞液。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式